Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 12—December 2023
CME ACTIVITY - Synopsis

Invasive Nocardia Infections across Distinct Geographic Regions, United States

Simran Gupta1, Leah M. Grant, Harry R. Powers, Kathryn E. Kimes2, Ahmed Hamdi3, Richard J. Butterfield, Juan Gea-Banacloche4, Prakhar Vijayvargiya5, D. Jane Hata, Diana M. Meza Villegas, Adrian C. Dumitrascu, Dana M. Harris, Razvan M. Chirila, Nan Zhang, Raymund R. Razonable, Shimon Kusne, Salvador Alvarez, and Holenarasipur R. VikramComments to Author 
Author affiliations: Mayo Clinic Arizona, Phoenix, Arizona, USA (S. Gupta, L.M. Grant, K.E. Kimes, R.J. Butterfield, J. Gea-Banacloche, N. Zhang, S. Kusne, H.R. Vikram); Mayo Clinic Jacksonville, Jacksonville, Florida, USA (H.R. Powers, D.J. Hata, D.M. Meza Villegas, A.C. Dumitrascu, D.M. Harris, R.M. Chirila, S. Alvarez); Mayo Clinic Rochester, Rochester, Minnesota, USA (A. Hamdi, P. Vijayvargiya, R.R. Razonable)

Main Article

Table 3

Antimicrobial susceptibilities based on Nocardia spp. in study of invasive Nocardia infections across 3 distinct geographic regions, United States*

Species No. 
isolates Susceptibility
AM/CL CEF CTX IMP CIP MOX CLA AMI TOB DOX MIN TMP/SMX LIN
N. abscessus
 17
 82
 82
 94
 59
 0
 14
 41
 100
 94
 88
 88
 94
 100
N. brevicatena/N. paucivorans
 5
 50
 75
 100
 100
 100
 100
 100
 100
 100
 100
 100
 100
 100
N. cyriacigeorgica
 68
 6
 28
 60
 97
 2
 3
 2
 99
 99
 6
 9
 100
 100
N. farcinica
 47
 96
 4
 4
 87
 57
 88
 4
 100
 0
 0
 6
 100
 100
N. nova complex
 51
 4
 51
 12
 98
 4
 7
 100
 98
 6
 2
 18
 100
 100
N. transvalensis complex
 12
 92
 17
 58
 8
 58
 100
 0
 8
 0
 0
 17
 100
 100
N. brasiliensis
 13
 100
 0
 0
 15
 0
 46
 0
 100
 100
 8
 0
 100
 100
N. wallacei
 13
 92
 8
 67
 0
 58
 100
 0
 25
 0
 17
 50
 100
 100
N. veterana
 5
 0
 60
 20
 100
 0
 0
 100
 100
 20
 0
 20
 100
 100
Other†
 37
 11
 44
 61
 78
 42
 61
 50
 94
 86
 47
 67
 92
 97
Total 268 40 33 40 78 24 40 33 91 51 17 27 99 100

*AM/CL, amoxicillin/clavulanic acid; CEF, cefepime; CTX, ceftriaxone; IMP, imipenem; CIP, ciprofloxacin; MOX, moxifloxacin; CLA, clarithromycin; AMI, amikacin; TOB, tobramycin; DOX, doxycycline; MIN, minocycline; TMP/SMX, trimethoprim/sulfamethoxazole; LIN, linezolid †Other species (n<5 each): N. amikacinitolerans (1), N. asiatica (1), N. asteroides complex (3), N. beijingensis (3), N. carnea (1), N. cerradoensis (1), N. exalbida (1), N. flavorosea (1), N. kruczakiae (1), N. niwae (2), N. otitidiscaviarum (1), N. pseudobrasiliensis (4), N. puris (1), N. takedensis (3), N. vermiculata (1), N. vinacea (1), and N. yamanashiensis (1); no species identified (9)

Main Article

1Current affiliation: Simran Gupta, Massachusetts General Hospital & Brigham and Women’s Hospital, Boston, Massachusetts, USA.

2Current affiliation: Kathryn E. Kimes, Honor Health, Phoenix, Arizona, USA.

3Current affiliation: Ahmed Hamdi, Baylor College of Medicine, Houston, Texas, USA.

4Current affiliation: Juan Gea-Banacloche, National Institute for Allergy and Infectious Diseases, Bethesda, Maryland, USA.

5Current affiliation: Prakhar Vijayvargiya, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Page created: September 26, 2023
Page updated: November 17, 2023
Page reviewed: November 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external